Acorda, Mylan reach settlement for Ampyra generic

Acorda Therapeutics Inc. (NASDAQ:ACOR) reached a conditional settlement with Mylan N.V. (NASDAQ:MYL) that would allow Mylan to market a generic version

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE